Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Whether ICIs combined with chemotherapy can improve outcomes in EGFR -mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated wi...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-08, Vol.11 (1), p.16122-16122, Article 16122
Main Authors: Shen, Chia-I, Chao, Heng-Sheng, Shiao, Tsu-Hui, Chiang, Chi-Lu, Huang, Hsu-Ching, Luo, Yung-Hung, Chiu, Chao-Hua, Chen, Yuh-Min
Format: Article
Language:English
Subjects:
692/4028
692/4028/67/1059
692/4028/67/1612
692/4028/67/395
692/4028/67/580
Chemotherapy
Epidermal growth factor receptors
Humanities and Social Sciences
Immunotherapy
Lung cancer
multidisciplinary
Mutants
Mutation
Non-small cell lung carcinoma
Patients
Science
Science (multidisciplinary)
Small cell lung carcinoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Whether ICIs combined with chemotherapy can improve outcomes in EGFR -mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated with ICIs or ICIs combined chemotherapy (ICI + C). Total 30 patients were included. The ORR were 9.1% and 25.0% for the ICI and ICI + C groups. The ICI + C group showed the trend of longer progression-free survival and overall survival periods. Patients without the T790M mutation had a significantly longer PFS than did those without this mutation (4.23 [95% CI: 2.75–5.72] vs. 1.70 [95% CI: 0.00–3.51] months, HR:4.45, p  = 0.019). ICIs combined with chemotherapy tended to be more effective than ICIs alone in pretreated EGFR -mutant NSCLC. The T790M mutation may be a potential biomarker.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-95628-w